[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT03184090 : Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC|
|Ages||Min: 18 Years Max: N/A|
- Pre- and postmenopausal women age ? 18 years (Premenopausal women must be treated with
LHRH analogues for at least 28 days prior to study entry)
- Hormone receptor-positive [estrogen receptor (ER) and/or progesterone receptor (PR)]
- Locally advanced or mBC that had previously received no more than two prior lines of
endocrine therapy and no more than one prior line of chemotherapy for advanced
- Inmmediate previous treatment with palbociclib in combination with endocrine therapy
had achieved clinical benefit during palbociclib-based treatment
- Evidence of measurable and biopsable metastatic disease is required
- Confirmed disease progression on immediate previous palbociclib plus endocrine
- Last dose of palbociclib administered no later than eight weeks and not earlier than
three weeks from study entry.
- No prior use of at least one of the reasonable endocrine therapy options: tamoxifen,
fulvestrant, letrozole/anastrozole, or exemestane.
- Patients agree to collection of blood samples (liquid biopsy) and collection of
metastatic tumour sample (biopsy) at the time of inclusion and progression (if
- Adequate organ function.
- Resolution of all acute toxic effects of prior anti-cancer therapy or surgical
- HR or HER2 unknown disease.
- HER2-positive disease based on local laboratory results [performed by
immunohistochemistry/fluorescence in situ hybridization (FISH)].
- Locally advanced breast cancer candidate for a local treatment with a radical
- Formal contraindication to endocrine therapy.
- Progressing central nervous system (CNS) disease.
- Patients with exclusive non-measurable/evaluable disease.
- Other malignancies within the past five years except adequately treated basal cell or
squamous cell skin cancer or carcinoma in situ of the cervix.
- Major surgery (defined as requiring general anaesthesia) or significant traumatic
injury within four weeks of start of study drug, or patients who have not recovered
from the side effects of any major surgery, or patients that may require major surgery
during the course of the study.
- Patients with an active bleeding diathesis, previous history of bleeding diathesis, or
anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon
as it is used as prophylaxis intention).
- Have a serious concomitant systemic disorder (i.e., active infection including HIV, or
cardiac disease) incompatible with the study (at the discretion of investigator).
- Are unable to swallow tablets.
- History of malabsorption syndrome or other condition that would interfere with enteral
- Chronic daily treatment with corticosteroids with a dose of ?10 mg/day
methylprednisolone equivalent (excluding inhaled steroids).
- QTc >480 msec on basal assessments, personal history of long or short QT syndrome,
Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).
- Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging
drug (i.e., hypocalcemia, hypokalemia, or hypomagnesemia).
- Known hypersensitivity to any palbociclib excipients.
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03184090
| Link to official Clinicaltrials.gov listing